logo
Plus   Neg
Share
Email

AstraZeneca: Roxadustat Phase III Pooled Analyses Show Positive Efficacy

AstraZeneca plc (AZN.L,AZN) and FibroGen Inc. have reported pooled efficacy and cardiovascular safety analyses from the Phase III programme assessing roxadustat for the treatment of patients with anaemia from chronic kidney disease. The company said the results demonstrated the potential of roxadustat to address significant unmet medical needs among patients with anaemia from chronic kidney disease, particularly for those who have recently started dialysis.

The primary efficacy endpoint was achieved in the pooled analyses for non dialysis-dependent and dialysis-dependent patients, and in all individual Phase III trials. The study data will form part of the regulatory submission in the US, which is anticipated in the fourth quarter of 2019.

Mene Pangalos, Executive Vice President, BioPharmaceuticals, R&D, said: "The pooled analyses showed incident dialysis patients receiving roxadustat had a lower risk of cardiovascular events which is important as these patients may experience higher rates of morbidity and mortality than those on stable dialysis."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
eBay Inc. (EBAY) Wednesday reported a fourth-quarter profit that trumped Wall Street analysts' estimates, as did revenues. However, shares of the company slipped over 5% after the company issued a weak outlook for the first quarter. eBay's fourth-quarter profit dropped to $558 million or $0.69 per... Apple Inc. (AAPL) Wednesday reported a first-quarter profit that trumped Wall Street estimates, as the iPhone maker reported its "highest quarterly revenue ever" driven by strong demand for its iPhone 11 and 11 Pro models during the holiday season. The tech giant also issued a strong revenue outlook... New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry.
Follow RTT
>